Gene therapy approaches for the selective killing of cancer cells

被引：17

作者：

Westphal, EM

von Melchner, H

机构：

[1] Univ Frankfurt, Sch Med, Lab Mol Hematol, D-60590 Frankfurt, Germany

[2] Univ Frankfurt, Sch Med, Dept Pharmacol, D-60590 Frankfurt, Germany

来源：

CURRENT PHARMACEUTICAL DESIGN | 2002年 / 8卷 / 19期

关键词：

D O I：

10.2174/1381612023393927

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This review describes gene therapy strategies that take advantage of defective signal transduction pathways to selectively kill cancer cells without adversely affecting normal cells. The distinctive features of cancer cells currently exploited by gene therapy include mitosis, cell permissiveness to infection, specific protease activity, and the activity of the p53, Rb/E2F and wnt/catenin signal transduction pathways. In most cases, proof of concept has been obtained in vitro and in vivo, but only a few approaches made it to the clinic. Overall, the clinical success rate has been disappointing and it is concluded that the gene therapy of cancer requires more innovation and hard work before its potential can be fully realized.

引用

页码：1683 / 1694

页数：12

共 118 条

[1] In vitro cell-free conversion of noninfectious moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein [J].